Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group

BACKGROUND: A phase I/II study to define the maximum tolerated dose (MTD) of biweekly docetaxel/cisplatin/5-fluorouracil (DCF) plus panitumumab (P), its efficacy, and tolerability as first-line treatment in advanced gastroesophageal cancer. METHODS: In phase I part, patients with unresectable locall...

Descripción completa

Detalles Bibliográficos
Autores principales: Kentepozidis, Nikolaos, Economopoulou, Panagiota, Liontos, Michael, Kotsakis, Athanasios, Boukovinas, Ioannis, Vardakis, Nikolaos, Kontopodis, Emmanouil, Prinarakis, Efthimios, Skaltsi, Teressa, Souglakos, John, Georgoulias, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191861/
https://www.ncbi.nlm.nih.gov/pubmed/30386120
http://dx.doi.org/10.20524/aog.2018.0311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191861/
https://www.ncbi.nlm.nih.gov/pubmed/30386120
http://dx.doi.org/10.20524/aog.2018.0311

Ejemplares similares